Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Allegretti M, et al. Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z. Mol Cancer. 2021. PMID: 34839818 Free PMC article. No abstract available.
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer.
Ganci F, Allegretti M, Frascolla C, Spinella F, Rollo F, Sacconi A, Valentina P, Palcau AC, Manciocco V, Vescovo M, Cotroneo E, Blandino F, Benevolo M, Covello R, Muti P, Strano S, Vidiri A, Fontemaggi G, Pellini R, Blandino G. Ganci F, et al. Among authors: allegretti m. Biomark Res. 2024 Mar 5;12(1):32. doi: 10.1186/s40364-024-00576-y. Biomark Res. 2024. PMID: 38444004 Free PMC article.
Correction: Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer.
Ganci F, Allegretti M, Frascolla C, Spinella F, Rollo F, Sacconi A, De Pascale V, Palcau AC, Manciocco V, Vescovo M, Cotroneo E, Blandino F, Benevolo M, Covello R, Muti P, Strano S, Vidiri A, Fontemaggi G, Pellini R, Blandino G. Ganci F, et al. Among authors: allegretti m. Biomark Res. 2024 Mar 26;12(1):37. doi: 10.1186/s40364-024-00582-0. Biomark Res. 2024. PMID: 38532476 Free PMC article. No abstract available.
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P, Valenti F, Allegretti M, Pallocca M, De Nicola F, Ciuffreda L, Fanciulli M, Scalera S, Buglioni S, Melucci E, Casini B, Carosi M, Pescarmona E, Giordani E, Sperati F, Jannitti N, Betti M, Maugeri-Saccà M, Cecere FL, Villani V, Pace A, Appetecchia M, Vici P, Savarese A, Krasniqi E, Ferraresi V, Russillo M, Fabi A, Landi L, Minuti G, Cappuzzo F, Zeuli M, Ciliberto G. Giacomini P, et al. Among authors: allegretti m. J Transl Med. 2023 Oct 16;21(1):725. doi: 10.1186/s12967-023-04595-5. J Transl Med. 2023. PMID: 37845764 Free PMC article.
Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA).
Gasparello J, Allegretti M, Tremante E, Fabbri E, Amoreo CA, Romania P, Melucci E, Messana K, Borgatti M, Giacomini P, Gambari R, Finotti A. Gasparello J, et al. Among authors: allegretti m. J Exp Clin Cancer Res. 2018 Jun 26;37(1):124. doi: 10.1186/s13046-018-0788-1. J Exp Clin Cancer Res. 2018. PMID: 29941002 Free PMC article.
156 results